Immunogenicity and Safety of GSK Biologicals' Inactivated Hepatitis A Vaccine (Havrix) Co-administered With GSK Biologicals' DTaP Vaccine (Infanrix) and Aventis Pasteur's Haemophilus b Conjugate Vaccine (ActHIB) in Healthy Children 15 Months of Age

Trial Profile

Immunogenicity and Safety of GSK Biologicals' Inactivated Hepatitis A Vaccine (Havrix) Co-administered With GSK Biologicals' DTaP Vaccine (Infanrix) and Aventis Pasteur's Haemophilus b Conjugate Vaccine (ActHIB) in Healthy Children 15 Months of Age

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Dec 2016

At a glance

  • Drugs Hepatitis A vaccine inactivated (Primary) ; DTaP vaccine; Hib vaccine conjugate
  • Indications Diphtheria; Haemophilus infections; Hepatitis A; Pertussis; Tetanus
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 13 Apr 2011 Results published in the Pediatric Infectious Disease Journal.
    • 14 Sep 2008 Official Title amended as reported by ClinicalTrials.gov
    • 14 Sep 2008 Primary endpoint identified as antibody level and seroprotection rate as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top